These are further comments on Boulware's previous study published in The New England Journal of Medicine where his previous study was published (on 3 June 2020). He also conclude then that hydroxychloroquine was not of any benefit rather than conclude further study is required to confirm the benefit he had found but was not statistically significant due to his sample size:
"We can draw three conclusions. First, hydroxychloroquine might be effective in early treatment, since the absence of evidence is not evidence of absence. Second, a larger trial involving participants with a virologic diagnosis should be conducted to detect a meaningful early treatment effect (e.g., a trial involving 8000 participants could detect a reduction in the incidence of symptomatic Covid-19 from 15.0% to 12.5%). Third, other trials examining preexposure prophylaxis and early postexposure prophylaxis should be considered."
